Rinica Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 22-12-2024
- Paid Up Capital ₹ 0.10 M
as on 22-12-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2021)
- Profit 72.74%
(FY 2021)
- Ebitda 72.74%
(FY 2021)
- Net Worth -0.40%
(FY 2021)
- Total Assets -29.98%
(FY 2021)
About Rinica Pharma
The Corporate was formerly known as Pantson Laboratories Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Rinica Pharma Private Limited India is Mayank Pant as CEO. Urmila Vemula, Virdeepsinh Sarvaiya, and Monica Pant serve as directors at the Company.
- CIN/LLPIN
U74999MH2014PTC256823
- Company No.
256823
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNavi Mumabi, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rinica Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayank Pant  | CEO | 15-May-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Virdeepsinh Sarvaiya | Director | 01-Aug-2014 | Current |
| Urmila Vemula | Director | 01-Jul-2021 | Current |
| Monica Pant | Director | 04-Mar-2019 | Current |
Financial Performance of Rinica Pharma.
Rinica Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 72.74% increase in profit. The company's net worth dipped by a decrease of 0.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rinica Pharma?
In 2021, Rinica Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pantson Pharma Private LimitedActive 12 years 3 monthsUrmila Vemula and Monica Pant are mutual person
- Neel Nayan Pharma Pvt LtdActive 35 years 1 month
Virdeepsinh Sarvaiya and Monica Pant are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rinica Pharma?
Unlock and access historical data on people associated with Rinica Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rinica Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rinica Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
